Statistical Image Reconstruction for High-Throughput Thermal Neutron Computed Tomography

Neutron Computed Tomography (CT) is an increasingly utilised non-destructive analysis tool in material science, palaeontology, and cultural heritage. With the development of new neutron imaging facilities (such as DINGO, ANSTO, Australia) new opportunities arise to maximise their performance through the implementation of statistically driven image reconstruction methods which have yet to see wide scale application in neutron transmission tomography. This work outlines the implementation of a convex algorithm statistical image reconstruction framework applicable to the geometry of most neutron tomography instruments with the aim of obtaining similar imaging quality to conventional ramp filtered back-projection via the inverse Radon transform, but using a lower number of measured projections to increase object throughput. Through comparison of the output of these two frameworks using a tomographic scan of a known 3 material cylindrical phantom obtain with the DINGO neutron radiography instrument (ANSTO, Australia), this work illustrates the advantages of statistical image reconstruction techniques over conventional filter back-projection. It was found that the statistical image reconstruction framework was capable of obtaining image estimates of similar quality with respect to filtered back-projection using only 12.5% the number of projections, potentially increasing object throughput at neutron imaging facilities such as DINGO eight-fold

Contextual Realization of the Universal Quantum Cloning Machine and of the Universal-NOT gate by Quantum Injected Optical Parametric Amplification

A simultaneous, contextual experimental demonstration of the two processes of cloning an input qubit and of flipping it into the orthogonal qubit is reported. The adopted experimental apparatus, a Quantum-Injected Optical Parametric Amplifier (QIOPA) is transformed simultaneously into a Universal Optimal Quantum Cloning Machine (UOQCM) and into a Universal NOT quantum-information gate. The two processes, indeed forbidden in their exact form for fundamental quantum limitations, will be found to be universal and optimal, i.e. the measured fidelity of both processes F<1 will be found close to the limit values evaluated by quantum theory. A contextual theoretical and experimental investigation of these processes, which may represent the basic difference between the classical and the quantum worlds, can reveal in a unifying manner the detailed structure of quantum information. It may also enlighten the yet little explored interconnections of fundamental axiomatic properties within the deep structure of quantum mechanics. PACS numbers: 03.67.-a, 03.65.Ta, 03.65.UdComment: 27 pages, 7 figure

Inhibition of dengue virus replication by novel inhibitors of RNA-dependent RNA polymerase and protease activities

Dengue virus (DENV) is the leading mosquito-transmitted viral infection in the world. With more than 390 million new infections annually, and up to 1 million clinical cases with severe disease manifestations, there continues to be a need to develop new antiviral agents against dengue infection. In addition, there is no approved anti-DENV agents for treating DENV-infected patients. In the present study, we identified new compounds with anti-DENV replication activity by targeting viral replication enzymes – NS5, RNA-dependent RNA polymerase (RdRp) and NS3 protease, using cell-based reporter assay. Subsequently, we performed an enzyme-based assay to clarify the action of these compounds against DENV RdRp or NS3 protease activity. Moreover, these compounds exhibited anti-DENV activity in vivo in the ICR-suckling DENV-infected mouse model. Combination drug treatment exhibited a synergistic inhibition of DENV replication. These results describe novel prototypical small anti-DENV molecules for further development through compound modification and provide potential antivirals for treating DENV infection and DENV-related diseases

A novel ultrafast-low-dose computed tomography protocol allows concomitant coronary artery evaluation and lung cancer screening

BACKGROUND:Cardiac computed tomography (CT) is often performed in patients who are at high risk for lung cancer in whom screening is currently recommended. We tested diagnostic ability and radiation exposure of a novel ultra-low-dose CT protocol that allows concomitant coronary artery evaluation and lung screening. METHODS: We studied 30 current or former heavy smoker subjects with suspected or known coronary artery disease who underwent CT assessment of both coronary arteries and thoracic area (Revolution CT, General Electric). A new ultrafast-low-dose single protocol was used for ECG-gated helical acquisition of the heart and the whole chest. A single IV iodine bolus (70-90 ml) was used. All patients with CT evidence of coronary stenosis underwent also invasive coronary angiography. RESULTS: All the coronary segments were assessable in 28/30 (93%) patients. Only 8 coronary segments were not assessable in 2 patients due to motion artefacts (assessability: 98%; 477/485 segments). In the assessable segments, 20/21 significant stenoses (> 70% reduction of vessel diameter) were correctly diagnosed. Pulmonary nodules were detected in 5 patients, thus requiring to schedule follow-up surveillance CT thorax. Effective dose was 1.3 ± 0.9 mSv (range: 0.8-3.2 mSv). Noteworthy, no contrast or radiation dose increment was required with the new protocol as compared to conventional coronary CT protocol. CONCLUSIONS:The novel ultrafast-low-dose CT protocol allows lung cancer screening at time of coronary artery evaluation. The new approach might enhance the cost-effectiveness of coronary CT in heavy smokers with suspected or known coronary artery disease

THE RISKS AND ADVANTAGES OF ANTI-DIABETES THERAPY IN THE POSITIVE COVID-19 PATIENT

The new Sars-Cov-2 (COVID-19) is causing thousands of deaths worldwide and has caused a global pandemic, one of the biggest health challenges ever faced in history. in the most severe cases, Sars-Cov-2 infection can cause fatal lung injuries. In this context, it is essential to recognise effective therapeutic agents against the virus. There are currently no direct and effective vaccines and antivirals available. People with pre-existing conditions, such as diabetes, and with chronic drug therapies in place may represent complex patients difficult to manage clinically during COVID-19 infection and at high risk of major complications. The regulation of blood glucose and the adoption of appropriate measures are critical aspects to consider for the diabetic patient in this pandemic period, especially in the patient with ongoing infection. In this article we describe the current evidence in the literature on the possible risks of side effects caused by taking antidiabetic drugs in the COVID-19 patient and the data on extra homeostasis glycemic activity useful to fight viral infection. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Peer Review History: Received 25 May 2020; Revised 8 June; Accepted 3 July, Available online 15 July 2020 Academic Editor: Essam Mohamed Eissa, Beni-Suef University, Egypt, [email protected] UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reviewer's Comments: Average Peer review marks at initial stage: 5.5/10 Average Peer review marks at publication stage: 7.0/10 Reviewer(s) detail: Dr. Heba M. Abd El-Azim,&nbsp;Damanhour University, Egypt,&nbsp;[email protected] Dr. George Zhu, Tehran University of Medical Sciences, Tehran, Iran, [email protected] Similar Articles: THE RELATIONSHIP BETWEEN DIABETES MELLITUS AND TUBERCULOSIS IN REVIEW OF PREVALENCE, DIAGNOSTICS AND PREVENTIO

USE OF COLCHICINE TO COUNTERACT THE STRONG HYPERINFLAMMATORY STATE INDUCED BY SARS-COV-2

Research in present time has been focusing on finding a specific SARS-CoV-2 vaccine or antiviral, which will probably be the therapeutic goal in the fight against the virus. In the meantime, scientific evidence shows that it is possible to have effective clinical improvements of infected patients in reducing the strong hyperinflammatory state. The SARS-CoV-2 infection is divided into three stages. The most serious phase is the third one where the immune system overdrives and launches an intense attack against itself. This is called "cytokine storm" and leads to tissue damage and often to death. Stopping the cytokine storm early is definitely an effective move; since March several studies have been evaluating how this can be an important pharmacological aspect. Blocking IL-6 or IL-1 inhibitors, for example, is already known to have wide efficacy, but they are not alone in being able to block the cascade of cytokines. This is a clinical pharmacology article and demonstrates how the use of colchicine, monotherapy or in combination in all three phases of SARS-CoV-2, controls inflammation and prevents patient death. Colchicine is safe and effective for treating SARS-CoV-2 patients in preventing inflammation and lung collapse and is certainly useful as an added remedy for other drugs. The advantage is certainly its safety profile much higher than that provided by other drugs, such as corticosteroids and immunosuppressive drugs. Note is the story of hydroxychloroquine: use has been banned due to its high toxicity. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Peer Review History: Received 25 May 2020; Revised 10 June; Accepted 6 July, Available online 15 July 2020 Academic Editor: Dr. Muhammad Zahid Iqbal, AIMST University, Malaysia, [email protected] UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reviewer's Comments: Average Peer review marks at initial stage: 5.5/10 Average Peer review marks at publication stage: 7.0/10 Reviewer(s) detail: Dr. Jennifer Audu-Peter,&nbsp;University of Jos, Nigeria, [email protected] Dr. Robert Tungadi, State University of Gorontalo, Indonesia, [email protected]

Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity

Takotsubo syndrome (TTS) is estimated to account for 1–3% of all patients presenting with suspected ST-segment elevation myocardial infarction. A sudden surge in sympathetic nervous system is considered the cause of TTS. Nonetheless, no specific recommendations have been provided regarding β-blocking therapy. Apart from specific contra-indications (severe LV dysfunction, hypotension, bradycardia and corrected QT interval &gt;500 ms), treatment with a β-blocker seems reasonable until full recovery of LV ejection fraction, though evidence is limited to a few animal studies, case reports or observational studies. In this review, we will reappraise the rationale for β-blocker therapy in TTS and speculate on the pathophysiologic basis for preferring non-selective agents with vasodilating activity over β1-selective drugs

Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment.

High-dose statin (HDS) therapy is recommended to reduce low-density lipoprotein cholesterol (LDL-C); however, some patients are unable to tolerate the associated side effects. Nutraceuticals have shown efficacy in lowering LDL-C. The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast rice, policosanol, and berberine) can lead to a higher proportion of high-risk patients achieving target LDL-C. A secondary objective was to assess the efficacy of triple combination LDS + EZE + ALP in resistant patients (LDL-C >70 mg/dl). A randomized, prospective, parallel-group, single-blind study was conducted in patients with coronary artery disease (n = 100) who had undergone percutaneous coronary intervention in the preceding 12 months, were HDS-intolerant, and were not at LDL-C target (<70 mg/dl) with LDS alone. Patients received either LDS + EZE or LDS + ALP. Of the 100 patients, 33 patients (66%) treated with LDS + EZE and 31 patients (62%) treated with LDS + ALP achieved target LDL-C after 3 months, which was maintained at 6 months. Patients who did not achieve the therapeutic goal received a triple combination of LDS + EZE + ALP for a further 3 months. At 6 months, 28 of 36 patients (78%) achieved LDL-C target. Overall, 92% of patients enrolled in this study were at target LDL-C at 6 months. No patients in any group experienced major side effects. In conclusion, in HDS-intolerant coronary artery disease patients, the combination of LDS plus EZE and/or ALP represents a valuable therapeutic option allowing most patients to reach target LDL-C within 3 to 6 months

Stellar Properties of z ~ 8 Galaxies in the Reionization Lensing Cluster Survey

Measurements of stellar properties of galaxies when the universe was less than one billion years old yield some of the only observational constraints of the onset of star formation. We present here the inclusion of \textit{Spitzer}/IRAC imaging in the spectral energy distribution fitting of the seven highest-redshift galaxy candidates selected from the \emph{Hubble Space Telescope} imaging of the Reionization Lensing Cluster Survey (RELICS). We find that for 6/8 \textit{HST}-selected $z\gtrsim8$ sources, the $z\gtrsim8$ solutions are still strongly preferred over $z\sim$1-2 solutions after the inclusion of \textit{Spitzer} fluxes, and two prefer a $z\sim 7$ solution, which we defer to a later analysis. We find a wide range of intrinsic stellar masses ($5\times10^6 M_{\odot}$ -- $4\times10^9$ $M_{\odot}$), star formation rates (0.2-14 $M_{\odot}\rm yr^{-1}$), and ages (30-600 Myr) among our sample. Of particular interest is Abell1763-1434, which shows evidence of an evolved stellar population at $z\sim8$, implying its first generation of star formation occurred just $< 100$ Myr after the Big Bang. SPT0615-JD, a spatially resolved $z\sim10$ candidate, remains at its high redshift, supported by deep \textit{Spitzer}/IRAC data, and also shows some evidence for an evolved stellar population. Even with the lensed, bright apparent magnitudes of these $z \gtrsim 8$ candidates (H = 26.1-27.8 AB mag), only the \textit{James Webb Space Telescope} will be able further confirm the presence of evolved stellar populations early in the universe.Comment: 8 pages, 3 figures, 2 table